Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20505766 | 0.86 | ALDH1A1 (0.54) | ALDH1A1MAPTMAPK1NPC1RAB9A | |
| SCHEMBL25640383 | 0.82 | ALDH1A1 (0.45) | ALDH1A1MAPTMAPK1NPC1RAB9A | |
| SCHEMBL746650 | 0.82 | ALDH1A1 (0.45) | ALDH1A1MAPTMAPK1NPC1RAB9A | |
| SCHEMBL12012134 | 0.82 | ALDH1A1 (0.45) | ALDH1A1MAPTMAPK1NPC1RAB9A | |
| SCHEMBL15372299 | 0.80 | MAPT (0.47) | ALDH1A1MAPTTSHRPOLB | |
| SCHEMBL11164498 | 0.80 | TDP1 (0.52) | ALDH1A1MAPTMAPK1NPC1RAB9A | |
| SCHEMBL1470582 | 0.80 | TDP1 (0.52) | ALDH1A1MAPTMAPK1NPC1RAB9A | |
| SCHEMBL292991 | 0.80 | TDP1 (0.52) | ALDH1A1MAPTMAPK1NPC1RAB9A | |
| SCHEMBL5073 | 0.80 | TDP1 (0.50) | ALDH1A1MAPTMAPK1NPC1RAB9A | |
| SCHEMBL9926 | 0.79 | ALDH1A1 (0.42) | ALDH1A1MAPTMAPK1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2861579-B9 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2018-08-29 | — | — | EP | disclosed |
| EP-2858988-B1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2018-02-28 | — | — | EP | disclosed |
| EP-2858988-B1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2018-02-28 | — | — | EP | disclosed |
| EP-2861579-B1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2018-02-21 | — | — | EP | disclosed |
| EP-2861579-B1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2018-02-21 | — | — | EP | disclosed |
| US-9278981-B2 | Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 | NOVARTIS AG (CH) | 2016-03-08 | — | — | US | disclosed |
| US-9278981-B2 | Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 | NOVARTIS AG (CH) | 2016-03-08 | — | — | US | disclosed |
| US-9278981-B2 | Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 | NOVARTIS AG (CH) | 2016-03-08 | — | — | US | disclosed |
| US-20150183801-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2015-07-02 | — | — | US | disclosed |
| US-20150183801-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2015-07-02 | — | — | US | disclosed |
| US-20140343086-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2014-11-20 | — | — | US | disclosed |
| US-20140343086-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2014-11-20 | — | — | US | disclosed |
| US-8829195-B2 | Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 | NOVARTIS AG (CH) | 2014-09-09 | — | — | US | disclosed |
| US-8829195-B2 | Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 | NOVARTIS AG (CH) | 2014-09-09 | — | — | US | disclosed |
| US-8829195-B2 | Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 | NOVARTIS AG (CH) | 2014-09-09 | — | — | US | disclosed |
| US-20130310395-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2013-11-21 | — | — | US | disclosed |
| US-20130310395-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2013-11-21 | — | — | US | disclosed |
| WO-2013171639-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2013-11-21 | — | — | WO | disclosed |
| WO-2013171640-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2013-11-21 | — | — | WO | disclosed |
| US-8252822-B2 | Heterocyclic compounds and uses as anticancer agents | ACEA BIOSCIENCES, INC. (US) | 2012-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343086-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | ABL1, ABL2, BCR | ALDH1A1 1602/4885MAPT 4248/4885MAPK1 230/4885 |
| US-20130310395-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | ABL1, ABL2, BCR | ALDH1A1 1602/4885MAPT 4248/4885MAPK1 230/4885 |
| US-20150183801-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | ABL1, ABL2, BCR | ALDH1A1 1494/4885MAPT 4601/4885MAPK1 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.